Cedazuridine/decitabine - Astex Pharmaceuticals

Drug Profile

Cedazuridine/decitabine - Astex Pharmaceuticals

Alternative Names: ASTX 727; Cedazuridine/Decitabine; Decitabine/cedazuridine; Decitabine/E7727; E-7727/decitabine

Latest Information Update: 16 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astex Pharmaceuticals
  • Class Antineoplastics; Aza compounds; Deoxyribonucleosides; Pyrimidine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Antimetabolites; Cytidine deaminase inhibitors; DNA methylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic myelomonocytic leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 19 Apr 2018 Astex Pharmaceuticals in collaboration Chiltern International with plans a phase I/II trial for Myelodysplastic Syndromes in June 2018 (NCT03502668)
  • 15 Feb 2018 Phase-III clinical trials in Myelodysplastic syndromes and Chronic myelomonocytic leukaemia in USA (PO) (NCT03306264)
  • 09 Dec 2017 Adverse events, efficacy and pharmacokinetics data from a phase II trial in Myelodysplastic syndromes and Chronic myelomonocytic leukaemia presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top